
Jianlong Wang, PhD
- ADJUNCT PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Developmental Biology, Epigenetics, Gene Expressions, Gene Regulation, Mass Spectrometry, Protein Complexes, Proteomics, Stem Cells, Transcription Factors, Transcriptional Activation and RepressionOur laboratory studies genetic and epigenetic regulation of embryonic stem cell pluripotency and somatic cell reprogramming, using genomic and proteomics approaches.
For more information, please visit the Wang Laboratory website.
Multi-Disciplinary Training Area
Development, Regeneration, and Stem Cells [DRS]Education
BS, Nankai University
MS, Institute of Microbiology, Chinese Academy of Sciences
PhD, University of Massachusetts at Amherst
Postdoc, Lineberger Comp. Cancer Center, University of North Carolina Chapel Hill
Postdoc, Children's Hospital Boston, Harvard Medical School
Instructor in Pediatrics, Harvard Medical School
-
2013
The Dr. Harold and Golden Lamport Research Award -
2013
Irma T. Hirschl and Weill-Caulier Trusts Career Scientist Award -
2007
Cell Development Award -
2000
LRFA Postdoctoral Fellowship -
1995
University Graduate Fellowship -
1988
University Undergraduate Award
Specific Clinical/Research Interest:
Genetic and epigenetic regulation of stem cell pluripotency and somatic cell reprogramming
Wang Lab Personnel:
Current Members
Xin Huang, Ph.D.
Title: Postdoctoral Fellow
Nationality: Chinese
Research Interest: Proteomics, Epigenetics
Email: xin.huang@mssm.edu
Diana Guallar, Ph.D.
Title: Postdoctoral Fellow
Nationality: Spanish
Research Interest: Transcriptional control of stem cell pluripotency
Email: diana.guallar@mssm.edu
Miguel Fidalgo, Ph.D.
Title: Postdoctoral Fellow
Nationality: Spanish
Research Interest: Naive and primed pluripotency and somatic cell reprogramming
Email: miguel.fidalgo-perez@mssm.edu
Francesco Faiola, Ph.D.
Title: Postdoctoral Fellow
Nationality: Italian
Research Interest: Protein-Protein Interaction and Stem Cell Pluripotency
Email: francesco.faiola@mssm.edu
Junjun Ding, Ph.D.
Title: Postdoctoral Fellow
Nationality: China
Research Interest: Epigenetic regulation of stem cell pluripotency
Email: junjun.ding@mssm.edu
Arven Saunders, M.S.
Title: PhD candidate
Nationality: USA
Research Interest: Nanog control of pluripotency and reprogramming
Former members:
Chandra P. Shekar, Ph.D.
Title: Postdoctoral Fellow (2009-2010)
Nationality: India
Research Interest: Novel pluripotency factors for stem cell pluripotency and development
Email: prabhc01@mssm.edu
Sarah H. Orkin, B.S. (2009-2010)
Title: Research Coordinator
Nationality: United States
Research Interest: Technician and lab manager
Summary of Research Studies:
Embryonic stem (ES) cells serve as a potentially inexhaustible source for tissue replacement in regenerative medicine due to their capability of unlimited self-renewal and multi-lineage differentiation. Vital cellular functions of ES cells require the coordinated action of a large number of proteins that assemble into an array of multi-protein complexes of distinct composition and structure (protein-protein interactions). In addition, physical interactions between regulatory pluripotency transcription factors and their target genes (protein-DNA interactions) provide insights into differential gene expression dictating the pluripotency program. Analysis of protein complexes encompassing intricate protein-protein and regulatory protein-DNA interactions is key to understanding stem cell pluripotency.
Recently, we tested the utility of in vivo biotinylation of transcription factors in mouse ES cells, and have established an in vivo biotinylation system for BirA-mediated specific biotinylation of critical pluripotency factors in mouse ES cells. We developed and optimized an approach for affinity purification of pluripotency protein complexes involving streptavidin capture of biotinylated proteins (dubbed bioSAIP) and demonstrated the feasibility of in vivo biotinylation for mapping global/chromosomal targets of many different transcription factors (dubbed bioChIP-chip). Utilizing the technologies we developed, we have constructed a protein interaction network surrounding the pluripotency factor Nanog in mouse ES cells (Wang et al., Nature 2006) and mapped an extended transcriptional network for pluripotency of mouse ES cells (Kim et al. Cell 2008). The network is highly enriched for factors known to be critical in ES cell biology and appears to function as a module for pluripotency. Pluripotency is maintained by many transcription factors that form a highly interconnected protein interaction network including the two homeobox proteins Nanog and Oct4, and a battery of associated proteins of known and unknown functions linking to multiple co-repressor pathways.
Further dissection of the pluripotency network in human ES cells (and induced pluripotent stem cells) and understanding molecular function of the novel factors should illuminate fundamental properties of stem cells and the process of cellular reprogramming, and ultimately lead to precise manipulation and realization of the full clinical therapeutic benefits of these unique cells. Therefore, my lab will be focusing on the following three research areas:
1) Defining protein-protein and protein-DNA interaction networks for pluripotency of human ES cells (and human iPS cells);
2) Dissecting molecular action of novel pluripotency factors on stem cell self-renewal and pluripotency;
3) Elucidating functional significance of novel pluripotency factors in early development and somatic cell reprogramming.
For more information, please visit the Wang Laboratory website.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wang did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.